These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20686324)

  • 1. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Yamasaki Y; Katakami N; Furukado S; Kitagawa K; Nagatsuka K; Kashiwagi A; Daida H; Kawamori R; Kaku K
    J Atheroscler Thromb; 2010 Nov; 17(11):1132-40. PubMed ID: 20686324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Kaku K; Daida H; Kashiwagi A; Yamashina A; Yamazaki T; Momomura S; Iwase T; Yamasaki Y; Nagatsuka K; Kitagawa K; Kawamori R
    Curr Med Res Opin; 2009 Dec; 25(12):2925-32. PubMed ID: 19835463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
    Hiukka A; Westerbacka J; Leinonen ES; Watanabe H; Wiklund O; Hulten LM; Salonen JT; Tuomainen TP; Yki-Järvinen H; Keech AC; Taskinen MR
    J Am Coll Cardiol; 2008 Dec; 52(25):2190-7. PubMed ID: 19095138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.
    Nakamura T; Matsuda T; Kawagoe Y; Ogawa H; Takahashi Y; Sekizuka K; Koide H
    Metabolism; 2004 Oct; 53(10):1382-6. PubMed ID: 15375799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones.
    Webb DR; Davies MJ; Gray LJ; Abrams KR; Srinivasan B; Das S; Taub N; Lawrence I; Sutton S; Khunti K
    Diabetes Obes Metab; 2010 Feb; 12(2):124-32. PubMed ID: 19922476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
    Koshiyama H; Shimono D; Kuwamura N; Minamikawa J; Nakamura Y
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3452-6. PubMed ID: 11443224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?
    Stein EA
    J Am Coll Cardiol; 2008 Dec; 52(25):2206-9. PubMed ID: 19095140
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    Fisher M
    Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
    Kanazawa I; Yamaguchi T; Yano S; Yamamoto M; Yamauchi M; Kurioka S; Sugimoto T
    Osteoporos Int; 2010 Dec; 21(12):2013-8. PubMed ID: 20130841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Pfützner A; Marx N; Lübben G; Langenfeld M; Walcher D; Konrad T; Forst T
    J Am Coll Cardiol; 2005 Jun; 45(12):1925-31. PubMed ID: 15963388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.